Clarivate/$CLVT
1D1W1MYTD1Y5YMAX
Capital at risk
About Clarivate
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas, while Europe, Middle East, and Africa account for around a quarter.
- Ticker
- $CLVT
- Sector
- Business services
- Primary listing
- NYSE
- Employees
- 12,000
- Headquarters
- London, United Kingdom
- Website
- www.clarivate.com
Clarivate Metrics
BasicAdvanced
$1.2B
-
-$0.51
1.39
-
Price and volume
Market cap
$1.2B
Beta
1.39
52-week high
$4.14
52-week low
$1.66
Average daily volume
4.3M
Financial strength
Current ratio
0.846
Quick ratio
0.721
Long term debt to equity
0.934
Total debt to equity
0.938
Interest coverage (TTM)
0.65%
Profitability
EBITDA (TTM)
914.8
Gross margin (TTM)
66.82%
Net profit margin (TTM)
-13.84%
Operating margin (TTM)
6.81%
Effective tax rate (TTM)
1.33%
Revenue per employee (TTM)
$200,000
Management effectiveness
Return on assets (TTM)
0.94%
Return on equity (TTM)
-7.01%
Valuation
Price to revenue (TTM)
0.52
Price to book
0.27
Price to tangible book (TTM)
-0.27
Price to free cash flow (TTM)
3.833
Free cash flow yield (TTM)
26.09%
Free cash flow per share (TTM)
0.504
Growth
Revenue change (TTM)
-3.50%
Earnings per share change (TTM)
-17.27%
3-year revenue growth (CAGR)
-2.57%
3-year earnings per share growth (CAGR)
-56.82%
What the Analysts think about Clarivate
Analyst ratings (Buy, Hold, Sell) for Clarivate stock.
Analyst projections of the future price of Clarivate stock.
Bulls say / Bears say
Selling Life Sciences & Healthcare for $600 million should leave Clarivate more focused on Academia & Government and Intellectual Property, with a pro forma recurring-revenue mix of about 92%. Management plans to use the proceeds to reduce debt, which could improve financial flexibility. (Clarivate)
The turnaround is producing operational leverage: first-half debt fell by more than $200 million, while second-quarter adjusted EBITDA margin held at 42.1%. Clarivate has also reaffirmed 2026 guidance for adjusted EBITDA of $980 million to $1.04 billion and free cash flow of $365 million to $435 million. (Clarivate)
New AI products could create a growth engine from Clarivate’s proprietary data. Web of Science Research Intelligence had 77 paying customers and a multimillion-dollar annualised contract value pipeline shortly after its global launch. (The Motley Fool, MarketScreener UK)
Underlying growth remains weak. Second-quarter organic revenue fell 1.5%, organic subscription revenue rose only 0.7%, and organic transactional revenue dropped 15.7%, showing that the subscription shift has not yet fully offset shrinking transactional activity. (Clarivate 10-Q)
Balance-sheet risk is still material: Clarivate had $4.25 billion of debt against $217.7 million of cash at the end of June. First-half free cash flow fell 23.5% year on year, while transaction and restructuring costs are expected to push 2026 cash flow towards the low end of guidance. (Clarivate 10-Q, The Motley Fool)
The Life Sciences & Healthcare disposal triggered a $221.7 million non-cash goodwill impairment and helped drive a $268.6 million second-quarter net loss. That highlights the risk that earlier acquisitions and asset values have not delivered the expected returns. (Clarivate 10-Q, Clarivate)
Data summarised monthly by Lightyear AI. Last updated on 21 Sept 2026.
Clarivate Financial Performance
Revenues and expenses
Clarivate Earnings Performance
Company profitability
Upcoming events
No upcoming events
Clarivate News
AllArticlesVideos
Funds containing Clarivate
AllEURGBPUSD
Fund name | Fund size | $CLVT weighting |
|---|---|---|
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.03% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.